9th International Congress on Spondyloarthropathies

Gent, Belgium
October 23 - 25, 2014

FINAL PROGRAMME

www.spa-congress.org
Dear Colleagues,

Welcome to the Ninth International Congress on Spondyloarthropathies. The rapid advances in SpA research since the last Congress two years ago have been remarkable indeed, and the field is nearly unrecognizable from the first SpA Congress in 1998, when little was known in SpA predisposition other than HLA-B27 and some infectious triggers, and there was little effective in SpA treatment than NSAIDs. This Congress will see the various themes that have dominated this research come together in a complementary and interactive manner showing a convergence of immunology, genetics, imaging, outcome studies and novel approaches to treatment.

The International Congress on Spondyloarthropathies has become the premier international research meeting focusing on SpA, and has provided a unique social and scientific forum for investigators worldwide to interact and collaborate. In the Ninth International Congress on Spondyloarthropathies we will see presentations from a broad range of researchers from the disciplines of molecular biology and cellular immunology, genetics, imaging, outcome studies and clinical research including imaging and clinical outcomes. The success of the meeting has been attributed to the high caliber of the research, a format which involves multidisciplinary expertise, and a venue which encourages both social and scientific interactions.

The program for the meeting will particularly focus on advances in genetics, including the complex networks of gene within and outside the MHC, in immunology, where in particular the critical importance of the IL17/IL23 axis and of antigen presentation will be explored, and the growing awareness of the role of the skin and intestinal mucosa in SpA pathogenesis will be highlighted, with focus in particular on skin and gut immunology and the microbiome, and on comorbidities complicating the course and prognosis of SpA. This underscores the importance of classification of early disease that will allow earlier diagnosis and novel therapeutic and behavioral interventions. The area of imaging has in particular been a challenge, and the growing awareness of the needs and challenges of utilizing this modality in early diagnosis and to identify those at highest risk for rapid progression and a poorer outcome will be explored. These major themes will be presented in a series of state-of-the-art lectures by international experts in the respective fields. The high quality of the abstracts is in particular an exciting aspect of this program, and outstanding work from young investigators worldwide will be presented in both poster and podium sessions. It is the goal of the meeting not only to contribute to disseminating these recent advances, but also to contribute to advancing the field of SpA research through communication and collaboration. This Congress has proved to be an ideal forum to build those synergies.

As Co-Presidents of the 2014 Congress, we extend a warm welcome to this exciting meeting and to the warmth and charm of the host city of Gent.

Martin Rudwaleit and John D. Reveille
Presidents,
9th International Congress on Spondyloarthropathies
Thursday, October 23

13.30 Welcome & Introduction
John Reveille & Martin Rudwaleit, Presidents

Opening Keynote Lectures
Chairs: John Reveille & Martin Rudwaleit

13.45 INV1 Basic science: The intestinal microbiome and the immune system
Gerard Eberl, Paris, France

14.30 INV2 Clinical science: Clinical trials - strengths, flaws, and limitations
Maarten Boers, Amsterdam, The Netherlands

Session I: Comorbidities and new targets in SpA – Sponsored by MSD
Chairs: Atul Deodhar & Filip Van den Bosch

15.15 INV3 CV risk and other risk factors: A view of axial SpA, RA and SLE
Mike T. Nurmohamed, Amsterdam, The Netherlands

15.45 INV4 Predicting treatment response in axial SpA: New and existing therapeutic targets
Filip Van den Bosch, Ghent, Belgium

16.15 Coffee Break

Session II: Novel pathways and opportunities in psoriatic arthritis and beyond – Sponsored by Janssen Pharmaceutica
Chairs: Josef Smolen & Désirée van der Heijde

16.45 INV5 Mapping the IL-23/IL-17 axis
Dirk Elewaut, Ghent, Belgium

17.15 INV6 Targets or strategies – The next steps in psoriatic arthritis management
Iain McInnes, Glasgow, UK

Session III: Current management of SpA – Sponsored by Pfizer
Chairs: Ruben Burgos-Vargas & Helena Marzo-Ortega

17.45 INV7 Axial SpA - met and unmet needs
Maxime Dougados, Paris France

18.15 INV8 Interpretation of MR imaging in axial SpA - bridging scientific studies and clinical practice
Robert Lambert, Edmonton, Canada

18.45 Opening Reception and Walking Dinner

Friday, October 24

08.30 INV9 Update on genetics of SpA
Matthew Brown, Woolloongabba, Australia

08.55 INV10 Revisiting MHC genes in SpA
Maxime Breban, Boulogne-Billancourt, France

09.20 INV11 HLA-B27, antigen presentation and ERAP1
Paul Bowness, Oxford, UK

Selected oral Presentations

09.45 O1 HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis
C. Jeanty, A. Noteuil, N. Jah, A. Sourisce, A. Wielgosik, I. Fert, M. Breban, C. André (France)

09.55 O2 Peptide handling by HLA-B27 subtypes influences their biological behavior, association with ankylosing spondylitis and susceptibility to ERAP1

10.05 O3 Discovery of T cell receptor clonotypes distinctive for HLA B27-positive ankylosing spondylitis by deep repertoire sequence analysis
M. Faham, V. Carlton, M. Moorhead, J. Zheng, T. Asbury, R.D. Inman (USA & Canada)

10.15 Coffee Break and Poster Session 1

Session V: Novel inflammatory pathways and targets – Sponsored by Novartis
Chairs: Hill Gaston & Georg Schett

11.15 INV12 Pathogenetic pathways in psoriasis and their relevance for PsA/SpA
Christopher Ritchlin, Rochester, USA

11.45 INV13 Targeting IL17 in axial SpA: From bench to bedside
Dominique Baeten, Amsterdam, The Netherlands

12.15 Lunch

State-of-the-Art Lecture
Chairs: Ruben Burgos-Vargas & Helena Marzo-Ortega

13.30 INV14 Juvenile spondyloarthritis: Clinical epidemiology update
Pamela Weiss, Philadelphia, USA
Friday, October 24

Session VI: ER stress and related responses
Chairs: Dirk Elewaut & Paul Bowness

14.00 INV15 ER stress in health and disease
Bart Lambrecht, Ghent, Belgium

14.25 INV16 Intestinal gamma delta T cells and stress
Adrian Hayday, London, UK

14.50 INV17 ER stress in SpA
Robert Colbert, Bethesda, USA

15.15 Coffee Break and Poster Session 2

Selected short abstract summaries
Chairs: Robert Colbert & Dominique Baeten

16.15 SO1 A novel monocyte-specific transcript underlies the chromosome 21Q22 intergenic genetic association in ankylosing spondylitis
K. Haynes, T. Kenna, E. Glazov, M.A. Brown, G.P. Thomas (Australia)

16.22 SO2 IL-23 expression and activation of autophagy in synovium and PBMCS of HLA-B27 positive patients with ankylosing spondylitis
B. Neerinckx, S.L. Carter, R.J. Lories (Belgium)

16.29 SO3 Stromal overexpression of transmembrane TNF induces experimental spondyloarthritis in mice
L.M. Van Duivenvoorde, M.N. Van Tok, D.L. Baeten (The Netherlands)

16.36 SO4 Gut derived IL-23R+CD3+CD4-CD8-CD56+ROCRc-Tbet+NKP44+ innate lymphoid cells are expanded in the peripheral blood, synovial fluid and bone marrow of ankylosing spondylitis patients
F. Ciccia, G. Guggino, A. Rizzo, L. Saieva, A.R. Giardina, R.Alessandro, G. Triolo (Italy)

16.42 SO5 Calgranulin levels are elevated in spondyloarthritis and reflect the presence of acute microscopic gut inflammation
H. Cypers, G. Varkas, L. Van Praet, C. Cuvelier, J. Roth, T. Vogl, D. Foell, M. Lavric, F. Van den Bosch, D. Elewaut (Belgium & Germany)

Friday, October 24

Session VII: Controversies in axSpA – Sponsored by UCB
Chairs: Roger Sturrock & Walter Maksymowych

17.00 INV18 Distinguishing nr-axSpA and AS by imaging: Feasible and how relevant?
Désirée van der Heijde, Leiden, The Netherlands

17.30 INV19 Are TNF-blockers true DMARDs in AS - How strong is the evidence?
Lianne Gensler, San Francisco, USA

19.30 Gala Dinner at the ‘Oude Vismijn’ (Old Fish Market)
Saturday, October 25

**Session VIII: What drives syndesmophyte formation in AS?**
Chairs: Xenofon Baraliakos & Joachim Sieper

08.30 INV20  **Inflammation and other factors relevant for radiographic progression in AS**
Robert Landewé, Heerlen, The Netherlands

08.55 INV21  **The mechanistic point of view of new bone formation in AS**
Rik Lories, Leuven, Belgium

09.20 INV22  **Which molecules might be relevant for blocking new bone formation in SpA?**
Georg Schett, Erlangen, Germany

**Selected oral Presentations**

09.45 O4  **Autoantibody to 14-3-3 ETA is a novel biomarker associated with MRI inflammation and radiographic progression in axial spondyloarthritis**
W.P. Maksymowych, S. Wichuk, M. Murphy, A. Marotta (Canada)

09.55 O5  **The relationship between inflammation, fatty lesions and syndesmophytes in AS: Results from GO-RAISE**
X. Baraliakos, G. Hermann Kay, S. Xu, B. Hsu, J. Braun (Germany & USA)

10.05 O6  **Disease activity in male smokers has a >10-fold amplified effect on radiographic damage in comparison with female non-smokers in ankylosing spondylitis**
S. Ramiro, A. van Tubergen, R. Landewé, C. Stolwijk, M. Dougados, F. van den Bosch, D. van der Heijde (The Netherlands, France & Belgium)

10.15 Coffee Break and Poster Session 3

**Selected oral Presentations**

11.15 O7  **Factors associated with radiographic sacroiliitis in spondyloarthritis (SPA): Results from cross-sectional and longitudinal analyses in a cohort of multiplex families**
F. Costantino, N. Zeboulon-Ktorza, R. Said-Nahal, M.A. D’Agostino, M. Breban (France)

11.25 O8  **Mortality and associated conditions in hospitalized ankylosing spondylitis patients**
K.W. Wysham, S.G. Murray, E.H. Yelin, L.S. Gensler (USA)

11.35 O9  **The effect of smoking cessation in ankylosing spondylitis – Results from the Scotland registry for ankylosing spondylitis (SIRAS)**
G.T. Jones, T. Ratz, L.E. Dean, G.J. Macfarlane, F. Atzeni on behalf of SIRAS (UK & Italy)

11.45 O10  **Targeting synovial mast cells in spondyloarthritis: A proof-of-concept study with the tyrosine kinase inhibitor nilotinib**

11.55 O11  **Objective evaluation of physical functioning after TNFi therapy in ankylosing spondylitis patients - A selection of three feasible performance-based tests**
S.F.E. van Weely, J. Dekker, M.P.M. Steultjens, J.C. van Denderen, M.T. Nurmohamed, B.A.C. Dijkmans, I.E. van der Horst-Bruinsma (The Netherlands & UK)

12.05 O12  **Clinical and imaging efficacy of etanercept in early non-radiographic axial spondyloarthritis: 48-week treatment data**

12.15 Lunch
Saturday, October 25

Session IX: The Future of SpA – Sponsored by abbvie
Chairs: Jürgen Braun & Robert Inman

13.30 INV23 How to identify new therapeutic targets in SpA?
Joachim Sieper, Berlin, Germany

14.00 INV24 Novel imaging modalities in SpA
Iris Eshed, Tel Hashomer, Israel

State-of-the-Art Lecture
Chairs: Jürgen Braun & Robert Inman

14.30 INV25 Personalized medicine using biomarkers: Reality or fiction?
Walter Maksymowych, Edmonton, USA

15.00 Closing Address
John Reveille & Martin Rudwaleit, Presidents

15.15 Farewell Reception

<table>
<thead>
<tr>
<th>Registration</th>
<th>Until 31/07/’14</th>
<th>As of 01/08/’14</th>
<th>As of 15/10/’14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant MD</td>
<td>€ 600,00</td>
<td>€ 650,00</td>
<td>€ 700,00</td>
</tr>
<tr>
<td>Participant Non-MD</td>
<td>€ 700,00</td>
<td>€ 750,00</td>
<td>€ 800,00</td>
</tr>
<tr>
<td>Student/Researcher</td>
<td>€ 350,00</td>
<td>€ 400,00</td>
<td>€ 400,00</td>
</tr>
<tr>
<td>Non-MD with Abstract*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gala Dinner on Friday</td>
<td>€ 50,00</td>
<td>€ 50,00</td>
<td>€ 50,00**</td>
</tr>
</tbody>
</table>

*Presenting author only
**If seats are available

The registration includes
The registration fee includes access to all lectures, to the Opening Reception and Walking Dinner, the lunches, coffee breaks and the Farewell Reception as indicated in the programme. Participants also have free access to the exhibition.

Participation into the Opening Reception & Walking Dinner and the Farewell Reception is free but pre-registration is mandatory.

Separate registration and payment is required to participate in the Gala Dinner.

How to Register
Register and pay online via secured booking form at www.spa-congress.org.

Click on ‘Registration’ for details and access to the online registration form. When your registration is completed successfully, you will receive an automatic confirmation. You can also print an invoice when you finalise your online registration.

Changes/Name Substitutions
After having submitted your registration it will be possible to make the following changes via the link on the confirmation that you will receive:
- Changes of names, choice of dinners, address details and hotel bookings
- Adding attendees to your registration
An administration fee € 100,00 will be charged if the congress secretariat has to make changes.

Payment
Payment is to be made by credit card. All major credit cards are accepted.

Cancellations
Cancellations received no later than August 31, 2014, entitle registered persons to a 50% refund. In order to cancel your registration and/ or hotel booking please contact Charlotte Schaeck: charlotte@medicongress.com.

Register on-line at www.spa-congress.org
A number of hotel rooms have been booked at special group rates, including breakfast and VAT. The below rates are only valid for reservations made through Medicongress. Housing requests are filled in order of receipt. If the hotel of your choice is filled, you will be assigned to another hotel. Hotel availability cannot be guaranteed after August 15.

Any requests for hotel accommodation must be accompanied by a credit card number, in order to secure the room. This credit card will not be charged by the organisers but only serves as a reservation guarantee. Participants will have to pay their hotel room and personal expenses at the reception of the hotel. In case of late cancellation or no show, the room will be charged on the Credit Card.

A hotel confirmation will be sent by email after receipt of the registration form and housing request and payment of the registration fee.

Each hotel has its proper cancellation policy. For details, see hotel accommodation section of www.spa-congress.be.

List of hotels and group rates for the SpA Congress:

**Ibis Gent Opera**
- Single room: € 106,50
- Double room: € 123,00
- Breakfast and city taxes are included.

**Ibis Gent Centrum St. Baafs Kathedraal**
- Single room: € 112,50
- Double room: € 129,00
- Breakfast and city taxes are included.

**Hotel Best Western – Cour St. Georges**
- Single room: € 125,00
- Double room: € 135,00
- Breakfast is included. City taxes are € 2,5 per person/night.

**Hotel Gravensteen**
- Standard Single room: € 119,00
- Standard Double room: € 129,00
- Executive Single room: € 139,00
- Executive Double room: € 149,00
- Breakfast is included. City taxes are € 2,50 per person/night.

**Novotel Gent Centrum**
- Standard Single room: € 138,00
- Double room: € 151,00
- Breakfast is included. City taxes are € 2,50 per person/night.

**Ghent River Hotel**
- Standard Single room: € 149,00
- Standard Double room: € 159,00
- Executive Single room: € 169,00
- Executive Double room: € 179,00
- Breakfast is included. City taxes are € 2,50 per person/night.

**Hotel de Flandre**
- Standard Single room: €149,00
- Standard Double room: € 159,00
- Executive Single room: € 169,00
- Executive Double room: € 179,00
- Breakfast is included. City taxes are € 2,50 per person/night.

**NH Gent Belfort**
- Single: € 139,00
- Double: € 154,00
- Breakfast is included. City taxes are €2,50 per person/night.

**Sandton Grand Hotel Reylof**
- Charme Single room: 159,00 euro
- Charme Double room: 169,00 euro
- Deluxe Single room: 179,00 euro
- Deluxe Double room: 189,00 euro
- Breakfast is included. City taxes are € 2,5 per person/night.
**General Information**

**Date**
Thursday, October 23 - Saturday, October 25, 2014

**Venue**
Flanders Opera House – Vlaamse Opera
Schouwburgstraat 3
9000 Gent
https://vlaamseopera.be/en

Flanders Opera House – Vlaamse Opera is located in the city centre, within walking distance from the hotels.

**Parking Facilities**
The centre of the city is largely car free. Hotels can be reached and participants are advised to park their cars at the car park ‘Sint Michiels’ which is located opposite ‘Het Pand’. In order to reach this parking, participants are advised to enter the city from the southern part of the ring road and to follow the signs P7 “Parking Sint Michiels”.

There are several car parks in the direct vicinity of Flanders Opera House:
- Parking Kouter - P5
- Parking Korte Meer
- Parking Savaanstraat

**How to reach Gent**
Gent can be reached easily by air, train, or car. Gent is located at approximately 50 km from Brussels.

**By air:** Brussels Airport (www.brusselsairport.be), home base of Brussels Airlines (www.brusselsairlines.be) is a major European airport. There are two direct trains per hour between Brussels airport and Gent. For detailed train information, go to: www.b-rail.be.

**By car:** As Belgium has the most dense highway network in Europe, Gent can be reached easily by car from all over Europe. Entering Gent from the E40 or the E17 motorway, follow the parking route (P-route)

**By train and tram:** Upon arrival at Gent St-Pieters railway station take tram 1 (every 6 minutes) and get off at stop Savaanstraat or Zonnestraat.

Detailed tourist information is also available at www.visitgent.be.

**Language**
The official congress language is English.

**Liability**
Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

**Organisation and Administration**
MEDICONGRESS
Noorwegenstraat 49
B-9940 Evergem, Belgium
Phone: +32 (0)9 218 85 85
Fax: +32 (0)9 344 40 10
E-mail: congresses@medicongress.com
Programme developed in collaboration with Wonder Reizen, Lic. A 5603
Social Programme

Opening Reception and Walking Dinner on Thursday, October 23
This Opening Reception and Walking Dinner will take place at Flanders Opera House and is included in the registration fee.

Gala Dinner on Friday, October 24
The Gala Dinner will take place at the ‘Oude Vismijn’ (Old Fish Market). Separate registration and payment is required to participate in the Gala Dinner.

Here centuries-old history and high-tech facilities go hand in hand. Opposite the Castle of the Counts lies the monumental gateway (1689) to the Old Fish Market. Neptune keeps watch over the Scheldt (male) and the Lys (female).

Farewell Reception on Saturday, October 25
The Farewell Reception will take place at Flanders Opera House and is included in the registration fee. Pre-registration however is required.